Gyre Therapeutics, Inc. GYRE Bad Debt Expense And Other Non Cash Items
Bad Debt Expense And Other Non Cash Items at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept gyre:BadDebtExpenseAndOtherNonCashItems.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s bad debt expense and other non cash items.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s bad debt expense and other non cash items?
- Gyre Therapeutics, Inc. (GYRE) reported bad debt expense and other non cash items of $195K in Q1 2026.
- How has Gyre Therapeutics, Inc.'s bad debt expense and other non cash items changed year-over-year?
- Gyre Therapeutics, Inc.'s bad debt expense and other non cash items increased by 3.7% year-over-year, from $188K to $195K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s bad debt expense and other non cash items?
- Over 2 years (2022 to 2025), Gyre Therapeutics, Inc.'s bad debt expense and other non cash items has grown at a 69.2% compound annual growth rate (CAGR), from $22K to -$63K.
- What does bad debt expense and other non cash items mean?
- Captures non-cash charges related to uncollectible accounts receivable and other miscellaneous non-cash operating adjustments. This metric provides insight into the quality of the company's receivables and the prudence of its accounting estimates. High values may indicate potential credit risk or aggressive revenue recognition practices.